Real world study of kabalatin

Real world study on the efficacy and safety of kabalatin in the treatment of Alzheimer's disease and dementia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048964

Enrollment

Unknown

Registered

2021-07-19

Start date

2021-07-19

Completion date

Unknown

Last updated

2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease and dementia

Interventions

case series:Rivastigmine Bitartrate Tablets

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, no gender limit; 2. Diagnosed mild to moderate Alzheimer's disease; 3. Clinical Dementia Rating (CDR) >= 1 point; 4. Treat patients with rivastigmine (Xianka); 5. The patient or the patient's legal representative understands and agrees to participate in this project, and voluntarily signs a written informed consent.

Exclusion criteria

Exclusion criteria: 1. Unable to insist on taking medication; 2. Those who cannot complete the follow-up required for the study.

Design outcomes

Primary

Measure	Time frame
Dementia score (CDR) decline rate after 24 weeks of treatment;Functional activity questionnaire scoring;Daily living ability;	—

Countries

China

Contacts

Public ContactMao Zhiqi

General Hospital of PLA

markmaoqi@163.com+86 18910155994

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026